Menagen–CKD Middle Eastern partnership

Home/Pharma News | Posted 03/09/2021 post-comment0

Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.

01 AA007239

The partnership, which was announced in July 2021, will allow the export of CKD’s Nesbell (darbepoetin alfa), an anaemia treatment biosimilar, to six countries in the Middle East: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.

Darbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia, commonly associated with chronic renal failure and cancer chemotherapy [1]. The originator product is Amgen’s Aranesp, which was approved in the US and Europe in 2001.

CKD’s Nesbell, was released in Korea and Japan in 2019 [1, 2]. It was co-developed by Japan’s Kyowa Hakko Kirin and the US’s Amgen. It is a second-generation anaemia biosimilar therapy and, compared to the first generation of drugs, the treatment significantly reduces the frequency of drug administration by using genetic engineering techniques.

Related articles
Biosimilar pipelines for South Korean firms Chong Kun Dang, DM Bio and HK Inno.n

Lotus to distribute CKD’s biosimilar darbepoetin alfa in South East Asia


The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares e intercambiabilidad en oncología

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares e intercambiabilidad en oncología

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of darbepoetin alfa []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010